0001193125-22-144991.txt : 20220509 0001193125-22-144991.hdr.sgml : 20220509 20220509161051 ACCESSION NUMBER: 0001193125-22-144991 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220509 FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Connect Biopharma Holdings Ltd CENTRAL INDEX KEY: 0001835268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40212 FILM NUMBER: 22905027 BUSINESS ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 BUSINESS PHONE: 86 512 5357 7866 MAIL ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 6-K 1 d296687d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2022

 

 

Commission File Number: 001-40212

 

 

Connect Biopharma Holdings Limited

(Translation of registrant’s name into English)

 

 

Science and Technology Park

East R&D Building, 3rd Floor

6 Beijing West Road, Taicang

Jiangsu Province, China 215400

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 4, 2022, Selwyn Ho, MB BS, informed Connect Biopharma Holdings Limited (the “Company”) of his intention to resign as Chief Business Officer of the Company to pursue a new opportunity. His last day at the Company will be June 30, 2022.

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 and S-8 (Registration Nos. 333-264340 and 333-254524, respectively) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: May 9, 2022     CONNECT BIOPHARMA HOLDINGS LIMITED
  By  

/s/ Steven Chan

    Name:   Steven Chan
    Title:   Chief Financial Officer